1. Home
  2. ESPR vs BWAY Comparison

ESPR vs BWAY Comparison

Compare ESPR & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.13

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$13.89

Market Cap

674.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESPR
BWAY
Founded
2008
2003
Country
United States
Israel
Employees
N/A
129
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
731.9M
674.2M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
ESPR
BWAY
Price
$3.13
$13.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
2
Target Price
$8.75
$13.25
AVG Volume (30 Days)
9.9M
148.7K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
60.71
N/A
EPS
N/A
N/A
Revenue
$403,135,000.00
N/A
Revenue This Year
N/A
$309.69
Revenue Next Year
$12.81
$26.21
P/E Ratio
N/A
$81.98
Revenue Growth
21.31
N/A
52 Week Low
$0.95
$10.61
52 Week High
$4.18
$26.63

Technical Indicators

Market Signals
Indicator
ESPR
BWAY
Relative Strength Index (RSI) 69.52 35.13
Support Level $3.11 $11.90
Resistance Level $3.18 $16.51
Average True Range (ATR) 0.01 0.52
MACD -0.03 -0.21
Stochastic Oscillator 75.00 2.12

Price Performance

Historical Comparison
ESPR
BWAY

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: